Navigation Links
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
Date:4/22/2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy

and New Insights into Mechanism of Action of Nitazoxanide

MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in four presentations made at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), held in Milan, Italy this week.

"These new studies confirm earlier data suggesting synergistic activity between nitazoxanide and peginterferon in genotype 4 patients and provide a first look at sustained virologic response in a limited number of genotype 1 patients," said Jean-Francois Rossignol, M.D., Director of the Romark Institute for Medical Research and discoverer of nitazoxanide. "These data also provide interesting insights into the mechanism of action of nitazoxanide and confirm previous findings related to its safety."

The four presentations include:

-- An oral presentation, titled, "Randomized Controlled Trial of

Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and

Peginterferon-Ribavirin in the Treatment of Patients with Chronic

Hepatitis C Genotype 4," reported final 24-week post-treatment

sustained virologic response (SVR) rates for the company's STEALTH C-1

trial.

In the trial, 96 treatment-naive patients with chronic hepatitis C

genotype 4 were randomized into three groups to receive either 48 weeks

of standard of care (SOC) treatment (n=40), 12 weeks of nitazoxanide

followed by 36 weeks of nitazoxanide plus peginterferon (a dual regimen,

n=28), or 12 weeks of nitazoxanide followed by 36 weeks of nitazoxanide

plus SOC with peginterferon plus ribavirin (a triple regimen, n=28). An

additional 24 interferon-experi
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- National Community Pharmacists Association (NCPA) CEO B. ... in response to a new report released ... number of generic drug costs increased substantially in 2013: ... expressed by NCPA and underscores the need for action ... Moreover, a 2015 survey of 700 community pharmacists concluded ...
(Date:5/28/2015)... 28, 2015  The U.S. Department of Justice (DOJ) ... and Rehab Medical Inc. to resolve a lawsuit that ... of a whistleblower lawsuit by two former employees of ... the direction of one of Orbit,s top executives, ... could obtain payment from Medicare for electric wheelchairs.  The ...
(Date:5/28/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/gsqwpp/proteomics ... new report "Proteomics - Technologies, Markets and ... report describes and evaluates the proteomic technologies that ... molecular diagnostics and practice of medicine in the ... 21st century. Most commonly used technologies are 2D ...
Breaking Medicine Technology:NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 2Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 3
... India, Oct. 10, 2011 Groupe Athena, Inc. (Pink sheets ... quarter ending September 30, 2011 which generated pretax earnings of ... for the same period. With the most recent strong quarter, ... share. The record quarterly revenue was significant in that it ...
... HILLS, N.J., Oct. 10, 2011 The New Jersey Patient ... in the Garden State, encourages men and their families to ... U.S. Preventive Services Task Force (USPSTF) recommended healthy men should ... of routine cancer screening. This decision was ...
Cached Medicine Technology:Groupe Athena, Inc. Reports Record First Quarter Revenues 2Groupe Athena, Inc. Reports Record First Quarter Revenues 3NJ Docs Say Cancer Detection Tool Saves Lives 2
(Date:5/28/2015)... (PRWEB) May 28, 2015 Three years ago, ... location for his Shore Vascular & Vein Center! ... circulatory system. It is his mission to provide the ... respect. , Dr. Jeffrey Gosin is Board Certified ... the University of Pennsylvania and Jefferson Medical College. He completed ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 AMVETS leaders ... grand prize winner Robert Davis of Newark, Del. AMVETS ... congratulate him on winning the $10,000 sweepstakes grand prize. ... over 100,000 entries from around the country for prizes ... drawing took place on May 21 at the AMVETS ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... ISMETT , a leading transplant hospital managed ... economy by €132.5 million in expenditure in 2013, generated nearly ... €73 million by retaining patients who otherwise would have traveled ... by the Battelle Memorial Institute. At the same time, the ... health care management that is transforming Sicily into a biomedical ...
(Date:5/28/2015)... May 28, 2015 " Trends Investing ” ... Report, which takes a look at small, medium, and large ... host of NewsWatch and business expert, conducted the business review ... users to where they should invest their money. , The ... concept. But doing it and knowing how to succeed ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2
... was no better than placebo, study finds , , MONDAY, ... (Trileptal) does not seem to prevent migraines, as once ... than 28 million Americans, and certain epilepsy drugs have ... headaches. For this reason, many assumed that oxcarbazepine would ...
... at Annual Meeting of the American Academy of ... ... NeoStrata today released new,clinical data that demonstrates significant benefits in combining,microdermabrasion ... products in improving the appearance,and texture of facial skin. The data ...
... for donations is spiraling for older couples wanting to start ... ... Radical shifts in parenting,trends have fertility experts at Reproductive Endocrinology Associates of,Charlotte ... in 2008 -- including new outreach through the Internet --,in efforts to ...
... the day that we,celebrate love approaches, many people with memory-impaired ... sustain a loving,relationship with someone who no longer knows who ... a new understanding of love itself., "It,s important to ... matters most is doing things that make him or her ...
... Show All 89 Inspected Pennsylvania Facilities Meet Federal,Standards, ... of,Environmental Protection reported today that all of the ... are operating within,the guidelines set forth by the ... each of Pennsylvania,s approximately 400 certified,mammography facilities annually ...
... saturate TV, radio, and print with anti-Meth ... ... The Illinois Meth Project,today launched a campaign to prevent first-time methamphetamine ... a research-based prevention program that educates people,about the dangers of Meth ...
Cached Medicine News:Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin 2Health News:Charlotte IVF Experts Issue Urgent Call for Egg Donors, Eye New Recruiting Tools 2Health News:Loving the Memory-Impaired: A New Perspective on Valentine's Day 2Health News:Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 2Health News:Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 3Health News:Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 4Health News:Illinois Meth Project Launches Large-Scale Meth Prevention Campaign 2Health News:Illinois Meth Project Launches Large-Scale Meth Prevention Campaign 3Health News:Illinois Meth Project Launches Large-Scale Meth Prevention Campaign 4
Cushing forceps. Insulated....
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size....
Fechtner Trabeculectomy Marker...
... when rotated at 8-10 rpm. Drums ... Light weight drum of professional quality ... mechanism. For use 24 to 30 ... and Pediatric Drums that can be ...
Medicine Products: